Olympus Corp.

Olympus Corp.

11.09
USD
+0.02
(+0.18%)
13.53BMarket Cap
Feb 12Next Earn

Q2 FY2027 · Earnings Call TranscriptNovember 10, 2026

Now we would like to start the Q&A session. My first question is about business environment, specifically North America.

What is your outlook in North America? In the first quarter, GI endoscopy did very well, but basically 3% increase and maybe this is slowing down.

Can you achieve the second-half target? The growth seems to be stagnating or slowing down.

What is the factor behind this? That's my first question.

Bob White

Thank you for the question. When we look at the first-half performance, it's right on where we thought it would be, and we saw very good growth in GIET, urology, and respiratory in North America.

In the core GI business in North America, the Q2 results really were the result of some deals that delayed closing in the quarter, and we expect those to close in the second half of the year. We actually do not see North America slowing down.

We like where we're positioned in North America.

Understood. My follow-up, my second question is about FDA response.

You have already explained this in your presentation. Effectiveness and also the sustainability of the remediation has to be demonstrated, proven.

What kind of impact will this have on finance and accounting in terms of cost, headcount increase, or how long will it take? Based on the most recent letter from FDA, does it impact your outlook on the cost on your financials?

Bob White

Thank you for the question, and let me reiterate that we certainly take this very seriously. The warning letter really classifies the inspections that took place last fall, and since January of last year, when we saw the observations, we accelerated our efforts in a number of the areas that I talked about.

As it relates to the cost, we believe that we have that within the budget as we look to continue to ensure we finish what we started here. Also, if we need to make additional trade-offs within it, we will, meaning that we will deliver our revenue and operating margin expansion while ensuring that we deliver on our quality system remediation.

Okay.

Understood, thank you.

I want to ask you about your guidance on slide 28, right? Slightly more detailed here.

Appears to me that excluding the tariff refund, the operating profit and net income guidance actually were revised down by about 3 3% and 8% respectively, right? Am I correct in my understanding?

If so, may I ask why that is the case?

Bob White

No, I actually don't believe you're correct. Our guidance was raised on revenue, operating margin, and earnings per share.

Maybe we can take this offline. I'm just comparing that to your first quarter results when you have a similar slide, right?

It looks like the absolute number of operating profit and net income appears to have declined excluding the tariff refund benefit.

Michael Parenti

We'll have to take that offline. To be truthful, that's not the situation.

In August, when we came out, we had a 14.9 at a managerial basis operating margin profit, and what we're showing now is something much higher than that. I just think we need to make sure that we're connected on the numbers.

I have a follow-up question on slide number 11, so that's GI endoscopy. It declined 3%, right, in constant currency in the second quarter, and you commented it's due to North America declined due to a one-time prior-year impact and extended deal timeline.

Can you explain this?

Bob White

In fact I'll have Keith weigh in here, but yeah, those were really the two factors when we looked at the performance in the quarter was we had royalty revenue from Swan in the prior year, and then we had a number of capital deals. Keith, why don't you characterize kind of how we're seeing the market in North America for GI?

Keith Boettiger

Look, we still see the underlying demand in North America as positive and good, and we still see strong demand for EVIS scopes. As Bob said and as you repeated, we saw some deals push off out of Q2 into the second half of the year and that one-time licensing payment.

Right now, we have confidence in the number going into the second half of the year and into our pipeline and into the team's ability to execute commercially as we close out the next two quarters.

Bob White

Building on Keith's point, one of the things we look at is the strength of the order book in all the regions, and in North America, we like the strength of the order book. Certainly timing is important that these deals land when we expect them to land, but we know that we've got that, and the second half looks good.

Thank you very much.

Thank you, Tony. With regard to the guidance, our team will get in touch with you offline for follow-up.

Adjusted OPM and EPS, we have increased the lower limit.

My question is about the FDA warning letter that you received in October. Yes, I hear your explanation, Bob, but unfortunately, Japanese analyst or investors are not very familiar with warning letter issue unfortunately.

We still have a bit of the concern on the issue because basically I think if I read the warning letter from FDA, all talk about CAPA things. Then I believe that the FDA really want to make sure kind of the matrix effectiveness as far as I understand.

Then you've been working on this issue for many years, but still this issue is pops up. I totally understand you give us a lot of explanation, but could you give us additional explanation how to tackle with the issues currently FDA is pointing out, especially about CAPA, matrix effectiveness, or all those issues?

Then I know that you are having new people to fix the issue, but what is going to change from the past to now, or in the future that kind of FDA-related issue. If you could follow up, that'd be helpful.

Thank you very much.

Bob White

Thank you very much for the question, and I'll have Brian Barry, our relatively new head of quality, jump in for a minute. Let me just get started, and your question is, why should we believe it's different this time?

I would offer you that's because since January, we've been doing things differently. We've invested in leaders across our functions.

We keep investing them to do the job right. Before, we closed actions, I think when the work was done.

Now we close them on evidence that the fix lasts, and this learning carries across to every site. Brian, I think it would be helpful, do you offer your observations here?

Brian Barry

Thanks, Bob. Thank you for the question.

In terms of what I've been seeing so far, the Olympus quality system is well-developed, and in general has the right content, but the procedures governing CAPA and complaint handling, MDR, process validation, etc., need to be executed more evenly across our facilities. When I think about it, we need to be able to demonstrate that we're doing things the same way at every site every single day.

We have to prove with evidence how we comply with quality system requirements. To your question, an important part of that is being able to demonstrate that corrective actions, when necessary, actually fix the problem, and as Bob said, are sustainable on the long run.

That's really what the warning letter is telling us. As Bob said, we're accelerating a number of things using industry experts to help guide and independently verify the next phase of our transformation.

First, corrective actions, as Bob said, will be closed on evidence that they are effective and sustainable, just not on work being finished. Two, we're investing in reliability engineering and advanced signal detection techniques to help us analyze service and customer complaint data in a more sophisticated and timely manner.

Last but not least, when it comes to process validation, we're making that a core skill at every single manufacturing site to help drive consistent product quality. As Bob said, we still have work to do, but we'll judge ourselves on our future inspection results as the key indicator of the effectiveness of our work going forward, and we'll continue to use our strategic pillars of innovation-driven growth, simplicity, and accountability to guide our work.

Bob White

Thanks, Brian.

Thank you very much. I got quick two follow-up question on your answers.

One is, what kind of time frame you're expecting to fix this, like matrix effectiveness or CAPA issues? 12 months or 6 months, if you could give us the guidance, that'll be helpful.

Also, the receive of the warning letter would affect your plan for the strategic option for the surgical business? That's two follow-up.

Thank you very much.

Bob White

Brian, I'll let you address the first part of that question in a minute relative to time frame and how we think about both. Our work is underway now, but of course, Brian will talk about when the FDA could return at their discretion.

The second part of your question was does our quality remediation work affect the strategic review of the surgical business? To be clear, the strategic review of the surgical business is still ongoing.

I don't have anything to report at this moment, and as I said, when I do, I certainly will disclose that to you. Make no mistake, quality, patient safety are at the top of our list, regardless of which business unit it is, and we'll work on remediating that across.

Certainly as we talked about and as Michael mentioned, we saw some early lifts of some ship holds, which meant that we had remediated some products and got those back into the marketplace. Hopefully that's helpful context.

Then, Brian, if you want to speak specifically the question about I think was the CAPA process and how we provide objective evidence that CAPAs are effective.

Brian Barry

Thanks, Bob. Thanks for the question.

We're currently in the process of improving our CAPA process. The focus there is really twofold.

Using Lean Six Sigma techniques, we're improving the efficiency and repeatability of our baseline process. Concurrent with that, we're also reviewing our overarching policy for CAPA and making sure that every site, as I said before, is implementing the requirements of that procedure consistently.

Really what we're working on is making sure that every site is being driven to readiness each and every day. We're going to continue to share progress with FDA, but the timing of future inspections is really up to them, and at this point, we don't have any dates for future inspections set.

Bob White

Thanks, Brian.

I have a question, two questions actually on China. My first question is that in the first half, Chinese business actuals are better or worse than the plan and budget?

That's my first question. Second or the second half, are you going to improve from the first half?

If that is no, there's any changes, is it reflected in the guidance?

Bob White

Yes, thank you for your questions, and I'll answer both of them. China is moving as expected, which is the decline narrowing each quarter, and Q2 was in line with our internal expectations.

Certainly we've spoken about in the past the policy shifts, the national VBP, our efforts on localization, but we expect gradual improvement as we talked about for the second half, and our guidance reflects accurately what our performance outlook is in China. Arigatou gozaimasu.

Thank you very much. I have a follow-up question for next year, for FY27, actually March 2027, for Chinese VBP, what's your outlook?

Sometimes in endoscope area, there might be a unit price decline, and price reduction is the rumors and concerns we hear. There are some our concerns, but from your point of view, for next fiscal year, what's your outlook of Chinese business, and what's the impact of VBP?

Bob White

Yes, thank you very much for the question. You're correct that we expect a national VBP broader than the regional programs we've seen with GIET particularly.

As we do our FY27 planning, we have that factored in based on what we know today. Importantly, while we certainly will see some pricing pressure on GIET in China, the underlying procedure demand is strong.

This is primarily a pricing challenge, and we're responding by shifting towards more differentiated products, developing different products for China, improving our commercial and cost structure. China remains an important long-term market for Olympus, and our focus is really on adapting the business to compete successfully in this new environment.

De, kakunin sasete...

Let me confirm once again. ET, you said endotherapy, is that the endotherapy?

How about endoscope per se, or EVIS X1? Unit price is not going to be a concern?

Do you think that the price is going to solid?

Bob White

No, we actually, to be clear in my answer, we see the pressure on GIET from the national VBP. We do not see further price erosion than what we've planned already in the other categories.

Thank you very much. That's all my questions.

I guess I'll ask Brian Barry about how you see the quality system at Olympus. I think you described it a little bit, but I think it's been last 3 months you've been probably been able to get to know more about Olympus's quality system vis-a-vis your former employer.

You said execution is the problem. The long warning letter seemed to suggest that the former management only put in a global CAPA system, but wasn't successful in changing the people and culture.

It would seem like a long haul changing people and culture, but my question is this: How do you see the quality culture at Olympus? Are there problems within the culture, and how will you change the quality culture?

That's my first question.

Brian Barry

Thank you for that question. Look, there is certainly a cultural element, but my conclusion is that we simply were not clear enough on the roles between the sites and the global functions.

We're working through that right now. We also didn't do enough oversight.

As Bob alluded to before, oversight is an important part of the verification process, and we need to make sure that we generate evidence of work completion and sustainability. That's fixable.

We're doing it. Relative to comparison with other places I've worked, look, again, I think the SOPs themselves, the procedures themselves, are largely fine.

We just need to work on that execution piece. Yes, that will drive cultural change, and we're committed to bringing in outside experts as well as leveraging our internal experts at a greater degree to make sure that the work is implemented consistently across all facilities, and any improvements that we make are sustainable.

Again, that's consistent with what the warning letter tells us.

Thank you. My final questions really for Bob.

Most Japanese analysts are not aware of what happens when the same facility or company receives repeated warning letters. The worst-case scenario is called consent decree.

It would seem that at least Hinode has received 2 warning letters. Can you give us any assurance that all of this will not proceed to a consent decree?

If it does, can Olympus still maintain the margin improvement target of 100 bps or better? That's my final question.

Bob White

Thank you, Kitani-san. Certainly I won't speculate on any regulatory outcomes.

We've not been advised of any FDA action beyond what we've disclosed, and as Brian and I've both talked about, the best protection against escalation is evidence that our fixes work, and that's how our effort goes. We've submitted a very comprehensive response to the warning letter, and again, I would offer to you we've accelerated action since January when we learned of the observations.

It'll take some time for the FDA to review our evidence in our responses. The FDA has asked for evidence of completion and sustainability, and that's what we'll do, and that's where our focus is.

I think you're right to point it out, but I don't believe that if we do our job, that's where this ends up.

About the margin expansion? Margin expansion target if you go into a consent decree?

Bob White

Look, I think our plan around revenue growth and margin expansion is fine as it is, and I'm standing behind it. Certainly we could develop a number of scenarios that would be disruptive to our plan, but I don't believe there's anything I see now that is disruptive to our revenue and operating margin plan of the nature you described.

Thank you.

I have two. The one of is you express about the confidence in achieving the guidance.

However, it seems you guys give in the range. Could you clarify whether the confidence is primarily around achieving the lower end or whether you are always confident in reaching the upper end of the range?

Thank you. This is my first question.

Bob White

Go ahead, Michael, you want to take that?

Michael Parenti

Sure. Hey, thanks for the question.

Look, and when we evaluated our guide for, second quarter for the full year, we had to evaluate where we are midway through the year, and like we talked about, we feel really comfortable with the performance through the first half of the year. When we think about some of the tailwinds that we have as we exit the first half and get into the second half, we feel very good about the catalysts for our GI business.

We talked about the ship holds returning earlier than expected. Then, of course, in the SG&A line, you'll see that in some of the reporting.

We've seen some of the efforts from the op model change working through the P&L. We feel very good about raising the bottom.

Again, I think for us, we want to make sure that there's space in the range in case something were to take place that we weren't expecting. I think we're comfortable in the middle part of that range for sure.

Bob White

Yep. That's right.

What else risk you are consider about in the half pass?

Bob White

Look, from my perspective, we have to execute our plan, which means we need to get products to the marketplace, we need to drive commercial execution, we absolutely will focus on our quality system remediation. We're focused on the things that are in our control, and I think the previous questions also talked about how we're thinking about China and the dynamics in the market there.

Importantly, I would offer you that ship holds and recalls, those are temporal, but the underlying demand for endoscopy-enabled care is not. We're in good markets with good businesses, and that's our focus.

Thank you. My second question is, since you have already been working on the quality improvement for several years, and following the important letter issued in December, could you clarify what field you now see as remain challenge in meeting FDA's expectations, and which things you believe have already been adequately addressed?

Bob White

Thank you for the question. As Brian and I said, when we think about the work that was done with Project Elevate, this was putting global systems in place for things like complaint handling, MDR, which means adverse event reporting, process validation.

Those were important foundational elements. Where we've been accelerating our efforts is to make sure that we execute consistently across all of our sites, and we have to do a better job of that.

Where we fix something in one site, make sure that that is fixed horizontally in other sites. What the agency has asked for is show us evidence that's sustainable.

Our focus now is really on showing that sustainable evidence. Two, we are investing in reliability engineering and advanced signal detection to analyze our customer complaints more vigorously.

Then three, as Brian mentioned, we're making sure that process validation, monitoring, and control become a core skill at every manufacturing site. I would say that's the work that we're on.

The reason I'm very pragmatic in our approach here is we've got a foundation, we need to improve our execution, and we need to execute consistently across our sites. That's what the FDA wants.

They want sustained evidence that we detect early and escalate our complaint data, and also that we have good control of non-conforming suppliers, and that we fix issues horizontally. As Brian mentioned, we're moving into this as the top priority to accelerate the work that we really began in January as the results of the inspection became known to us.

Of course, we didn't know how the agency was going to classify the inspections until the October warning letter, but that didn't stop us. We got to work right away in January.

Thank you. Totally understood.

Yeah. Thank you.

That's all.

Congratulations on a strong commercial performance. Bob, could you talk about the division-led operating model that you've implemented and how is that contributing to the commercial execution, please?

Bob White

Thanks, Steven. When we announced our revised strategy last November of innovation-driven growth, simplicity, and accountability, we believed in this middle pillar of simplicity that a pivot to a division-led operating model would streamline decision-making.

The other thing it did was it identified redundancies. When we talked about our execution of those position optimizations, and we've delivered on that commitment of the 24 billion yen run-rate savings, this has really enabled that.

This is just the first step. What we like about the division operating model is it continues to identify ways that we can drive efficiency and simplicity across Olympus.

We're not resting, and we're going to continue to focus on that.

Thanks very much.